Physician profile
Mark W Mulkey
NPI 1700872777
$800.15
in general payments reported to CMS, 2019-2025
16 companies · $74.13 in 2025
The $74.13 reported for 2025 was less than what a typical Plastic Surgery provider received nationally (typical 2025 total: $380).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $138 · 2020: $36.51 · 2022: $373 · 2023: $55.78 · 2024: $123 · 2025: $74.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $255.85 | 2019-2023 | Puraply |
| Allergan, INC. | $105.78 | 2019-2022 | |
| Depuy Synthes Sales INC. | $61.75 | 2020-2025 | Na |
| Sientra, INC. | $46.13 | 2022 | |
| Convatec INC. | $45.15 | 2024 | |
| Medtronic, INC. | $42.62 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $37.40 | 2024-2025 | |
| Axogen | $32.92 | 2019 | |
| Stryker Corporation | $28.93 | 2022-2023 | Spy-Phi System |
| Abbvie INC. | $27.84 | 2023-2024 | |
| Pacira Pharmaceuticals Incorporated | $23.88 | 2024 | Exparel |
| Smith+Nephew, INC. | $23.66 | 2019 | |
| Kerecis Limited | $20.05 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Solventum Corporation | $17.17 | 2025 | Prevena, V.A.C.Instill, Activ.A.C. |
| Molnlycke Health Care US, LLC | $16.26 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mulkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.